Biotechnology Acquisitions in 2026
-
March 7, 2026
- Buyer
- MGI Tech
- Target
- STOmics, CycloneSEQ
- Industry
- Biotechnology
- Location
- China
- Type
- Buyout
MGI Tech announced the acquisition of STOmics and CycloneSEQ to integrate long-read sequencing, short-read sequencing, and spatial omics technologies into a unified platform. The deal brings STOmics’ Stereo-seq spatial multi-omics tech and CycloneSEQ’s nanopore-based long-read sequencing systems in-house, supporting MGI’s “SEQALL+GLI+Omics” strategy and a more comprehensive end-to-end offering for researchers.
-
March 5, 2026
- Buyer
- Solabia
- Target
- Mibelle Biochemistry, Seqens' Botanical Actives and In-Vitro Diagnostics activity, Xebios Group
- Industry
- Biotechnology
- Location
- France
- Type
- Addon
Solabia, a Paris-headquartered biotech platform focused on natural active ingredients and diagnostics solutions, has agreed to acquire three complementary businesses: Mibelle Biochemistry, Seqens’ Botanical Actives and In-Vitro Diagnostics activity, and Xebios Group. The acquisitions broaden Solabia’s capabilities in natural cosmetic actives and expand its microbiological diagnostics footprint in Europe as the company accelerates its international expansion strategy.
-
March 5, 2026
- Buyer
- Candid Therapeutics, Rallybio Corporation
- Target
- Rallybio Corporation
- Industry
- Biotechnology
- Location
- Connecticut, United States
- Type
- Buyout
Clinical-stage biotechnology company Candid Therapeutics signed a merger agreement with Rallybio Corporation to create a combined company focused on developing T cell engager therapies for autoimmune diseases. The transaction is expected to close in mid-2026, pending customary approvals and conditions, and Candid also secured an oversubscribed private financing of more than $505 million led by healthcare institutional investors.
-
March 5, 2026
- Buyer
- Esperion Therapeutics
- Target
- Corstasis Therapeutics
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Esperion Therapeutics announced it has entered into a definitive agreement to acquire Corstasis Therapeutics for an upfront cash payment of $75 million, with potential milestone payments of up to $180 million. The deal is expected to add Enbumyst (bumetanide nasal spray) to Esperion’s cardiovascular portfolio, leveraging its commercial infrastructure to expand its cardiovascular franchise.
-
February 26, 2026
- Buyer
- Asahi Kasei
- Target
- Aicuris Anti-infective Cures AG
- Industry
- Biotechnology
- Location
- Germany
- Type
- Buyout
Asahi Kasei entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG, a German biopharmaceutical company, for approximately €780 million (about $919 million). The deal is expected to close in the first quarter of fiscal 2026, subject to customary conditions, and is intended to strengthen Asahi Kasei’s specialty pharmaceutical platform in severe infectious diseases.
-
February 23, 2026
- Buyer
- Axol Bioscience
- Target
- Newcells Biotech (ophthalmology business)
- Seller
- Newcells Biotech
- Industry
- Biotechnology
- Location
- Tyne and Wear, United Kingdom
- Type
- Divestiture
Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.
-
February 21, 2026
- Buyer
- Gilead Sciences
- Target
- Arcellx, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Gilead Sciences entered into a definitive agreement to acquire Arcellx, Inc. for $115 per share in cash plus a contingent value right of $5 per share, implying an equity value of about $7.8 billion. The deal is designed to give Gilead full control of Arcellx’s anito-cel (anito-cabtagene autoleucel) BCMA-directed CAR T therapy, eliminating profit-sharing and related payments while accelerating development and commercialization.
-
February 18, 2026
- Buyer
- Sensei Biotherapeutics, Inc.
- Target
- Faeth Therapeutics, Inc.
- Seller
- Faeth Therapeutics equityholders
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Sensei Biotherapeutics (Nasdaq: SNSE) has acquired clinical-stage Faeth Therapeutics in a stock-for-stock transaction that brings Faeth's lead oncology asset PIKTOR into Sensei's pipeline. Concurrently Sensei raised approximately $200 million in a private placement of Series B non-voting convertible preferred stock from a syndicate of institutional life-sciences investors to advance PIKTOR through Phase 2 topline data and initiate a Phase 1b breast cancer trial.
-
February 9, 2026
- Buyer
- Eli Lilly and Company
- Target
- Orna Therapeutics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Eli Lilly and Company has signed a definitive agreement to acquire Orna Therapeutics, valuing the deal at up to $2.4 billion. The acquisition is intended to expand Lilly’s genetic medicine and in vivo cell engineering capabilities, particularly for advancing in vivo CAR-T therapies using Orna’s circular RNA and lipid nanoparticle (LNP) platform.
-
- Buyer
- XOMA Royalty Corporation
- Target
- Generation Bio Co. (Generation Bio)
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
XOMA Royalty Corporation completed its previously announced tender offer to acquire all outstanding shares of Generation Bio common stock for $4.2913 per share in cash, plus one non-tradeable contingent value right (CVR). Following the tender offer, a subsidiary (XRA 7 Corp.) merged with and into Generation Bio, making Generation Bio a wholly owned subsidiary of XOMA Royalty.
-
February 4, 2026
- Buyer
- DT Cloud Star Acquisition Corporation
- Target
- PrimeGen US, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
PrimeGen US, Inc. entered into a definitive business combination agreement with DT Cloud Star Acquisition Corporation (a publicly traded SPAC), implying an equity value of approximately $1.5 billion. The transaction is expected to provide access to public markets capital to advance PrimeGen US’s stem cell and exosome therapies, with an anticipated closing in the second half of 2026 subject to approvals and customary closing conditions.
-
February 3, 2026
- Buyer
- Cycle Group Holdings Limited, AT2B, Inc.
- Target
- Applied Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Cycle Group Holdings Limited, through AT2B, Inc., completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. Applied is a clinical-stage biopharmaceutical company developing govorestat, an aldose reductase inhibitor for CNS rare metabolic diseases.
-
January 29, 2026
- Buyer
- Eclipse Bioinnovations (Eclipsebio)
- Target
- Terrain Bio
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Eclipse Bioinnovations (Eclipsebio) has acquired Terrain Bio to integrate Terrain's AI/ML RNA design models and R&D-scale mRNA manufacturing analytics into Eclipsebio's sequencing-based validation platforms. The deal creates an end-to-end Design, Make, Test platform intended to accelerate RNA therapeutic development by connecting computational design directly to experimental feedback.
-
January 29, 2026
- Buyer
- Demeetra AgBio
- Target
- Hera BioLabs
- Industry
- Biotechnology
- Location
- Kentucky, United States
- Type
- Buyout
Demeetra AgBio has completed the acquisition and full integration of Hera BioLabs, consolidating commercial rights to the hyperactive Super piggyBac transposase platform under Demeetra. The deal brings Hera’s in vitro services into Demeetra’s R&D, winds down Hera’s in vivo services, and positions Demeetra as the definitive commercial licensor for Super piggyBac across research, development, and biomanufacturing use cases.
-
January 28, 2026
- Buyer
- XenoTherapeutics, Inc., Xeno Acquisition Corp.
- Target
- Repare Therapeutics Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
XenoTherapeutics, Inc. and Xeno Acquisition Corp. acquired all outstanding shares of Repare Therapeutics Inc. via a statutory plan of arrangement. The deal was approved by Repare shareholders in January 2026 and the acquisition was completed with a per-share cash payment of approximately US$2.20 plus contingent value rights.
-
January 23, 2026
- Buyer
- GSK
- Target
- RAPT Therapeutics
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
GSK signed a definitive agreement to acquire RAPT Therapeutics for an aggregate equity value of about $2.2 billion, expanding its Respiratory, Immunology & Inflammation pipeline. The deal adds ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylaxis of food-allergy reactions.
-
January 22, 2026
- Buyer
- Gannet BioChem, Ampersand Capital Partners
- Target
- Laysan Bio
- Industry
- Biotechnology
- Location
- Alabama, United States
- Type
- Addon
Gannet BioChem, a PE-backed specialty CDMO, has acquired Laysan Bio, a maker of activated polyethylene glycol (PEG) reagents based in Arab, Alabama. The add-on expands Gannet BioChem's activated polymer and bioconjugation capabilities, strengthening its ability to support partners from early development through GMP manufacturing.
-
January 22, 2026
- Buyer
- KKR, TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee, Novo Holdings
- Target
- Sylvan
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Growth capital
KKR has completed an additional investment in Sylvan, a global mushroom spawn and fungal biotechnology company, with participation from TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee and a follow-on from Novo Holdings. The funding will support Sylvan’s expansion—increasing production capacity, strengthening R&D, developing new product categories and deeper growth across Asian markets—while KKR remains the company’s majority investor.
-
January 20, 2026
- Buyer
- EQT Life Sciences (LSP Dementia Fund), Gimv, Fountain Healthcare Partners, LifeArc, Carma Fund, Modi Ventures, Andera Partners, LBBW
- Target
- Exciva (EXCIVA GmbH)
- Industry
- Biotechnology
- Location
- Baden-Württemberg, Germany
- Type
- Growth capital
EQT Life Sciences (via its LSP Dementia Fund) and Gimv co-led a €51 million Series B in German clinical-stage biopharmaceutical company Exciva to fund a Phase 2 trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease. Additional participants included Fountain Healthcare Partners, LifeArc, Carma Fund, Modi Ventures, Andera Partners, LBBW and returning investors; proceeds will support multinational Phase 2 studies across the EU, United States and Canada.
-
January 20, 2026
- Buyer
- Taconic Biosciences, Inc.
- Target
- TransCure bioServices SAS
- Industry
- Biotechnology
- Location
- Haute-Savoie, France
- Type
- Buyout
Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.
-
January 16, 2026
- Buyer
- Zydus Lifesciences Limited, Zylidac Bio LLC
- Target
- Agenus Inc.
- Seller
- Agenus Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Zydus Lifesciences Limited has completed purchase agreements with Agenus Inc. to acquire Agenus' biologics manufacturing facilities and operations in Emeryville and Berkeley, California, and has established a U.S. CDMO subsidiary, Zylidac Bio LLC, to operate the assets. The deal includes exclusive manufacturing arrangements for Agenus' Phase 3 immuno-oncology candidates (botensilimab and balstilimab), exclusive commercialization rights for those assets in India and Sri Lanka, and an equity investment in Agenus via Zynext Ventures; regulatory approvals including CFIUS clearance were secured.
-
January 12, 2026
- Buyer
- Curi Bio
- Target
- Quvit Bio
- Industry
- Biotechnology
- Location
- South Korea
- Type
- Buyout
Curi Bio completed a full acquisition of South Korea-based Quvit Bio and has established Curi Bio Co., Ltd. as its Asia-Pacific commercial and operational hub. The deal integrates Quvit's imaging hardware, software and team to expand Curi Bio's localized sales, R&D and operational capabilities across South Korea, Japan and China.
-
- Buyer
- Acuitas Therapeutics
- Target
- RNA Technologies & Therapeutics (RNA T&T)
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Buyout
Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), deepening a long-standing collaboration to integrate RNA payload design and LNP delivery capabilities. The investment will support RNA T&T's growth—expanding its algorithmic RNA-sequence optimization platform and small-batch GMP production—while both companies continue to operate independently and offer streamlined capabilities to partners.
-
January 8, 2026
- Buyer
- Merck Sharp & Dohme LLC, Merck & Co., Inc.
- Target
- Cidara Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Merck Sharp & Dohme LLC (Merck & Co., Inc.) completed its cash tender offer and follow-on merger to acquire Cidara Therapeutics, Inc. for $221.50 per share, valuing the deal at about $9.2 billion. The acquisition adds Cidara’s late-stage, long-acting, strain-agnostic influenza antiviral candidate CD388 to Merck’s respiratory pipeline.
-
January 6, 2026
- Buyer
- Amgen
- Target
- Dark Blue Therapeutics
- Seller
- Oxford Science Enterprises, Bristol Myers Squibb, Evotec
- Industry
- Biotechnology
- Location
- Oxfordshire, United Kingdom
- Type
- Buyout
Amgen has acquired Dark Blue Therapeutics, an Oxford-based biotechnology company focused on targeted protein degraders for oncology, in a deal valued at up to $840 million including upfront and milestone payments. The acquisition adds Dark Blue's preclinical MLLT1/3 degrader program (DBT-3757) to Amgen's early oncology discovery efforts and will be integrated into Amgen's existing R&D organization.
-
January 6, 2026
- Buyer
- Artis BioSolutions
- Target
- Syngoi Technologies
- Seller
- Oak HC/FT, Columbus Venture Partners
- Industry
- Biotechnology
- Location
- Basque Country, Spain
- Type
- Buyout
Artis BioSolutions has signed a definitive agreement to acquire Syngoi Technologies, a Bilbao, Spain-based biotech developing enzymatic approaches for manufacturing synthetic DNA. The deal is intended to add fast, lower-cost synthetic DNA manufacturing to Artis’ gene-to-drug advanced-therapy platform, with Syngoi’s Bilbao GMP-ready facilities becoming part of Artis’ global footprint.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.